Abstract:Ischemic stroke, as a prevalent neurological disorder, often results in rapid increases in the production of reactive oxygen species (ROS) and inflammatory factors in the focal ischemic area. Though edaravone is an approved treatment, its effect is limited due to its weak ability to cross the blood-brain barrier (BBB) and short half-life. Other effective pharmacological treatment options are clearly lacking. In this study, PNIVDBrF-3-Eda (also named MG-3-Eda) was prepared using a thermo- and pH dual-responsive PNIVDBrF microgel. These were designed with a positively charged network, as synthesized by simultaneous quaternization cross-linking and surfactant-free emulsion copolymerization, to be loaded with the negatively charged edaravone. We then investigated whether such a targeted delivery of edaravone could provide enhanced neuroprotection. Cytotoxicity assays confirmed that the microgel (<1 mg/mL) exhibited promising cytocompatibility with no remarkable effect on cell viability, cell cycle regulation, or apoptosis levels. In vitro and in vivo experiments demonstrated that the microgels could successfully penetrate the blood-brain barrier where efficient BBB crossing was observed after disruption of the BBB due to ischemic injury. This enabled MG-3-Eda to target the cerebral ischemic area and achieve local release of edaravone. Treatment with MG-3-Eda significantly reduced the cerebral infarct area in transient middle cerebral artery occlusion (tMCAO) mice and significantly improved behavioral scores. MG-3-Eda treatment also prevented the reduction in NF200 expression, a neuronal marker protein, and attenuated microglia activation (as detected by Iba1) in the local ischemic area via local antioxidant and anti-inflammatory effects. A superior neuroprotective effect was noted for MG-3-Eda compared to that for free edaravone. Our results indicate that MG-3-Eda administration represents a clear potential treatment for cerebral ischemia via its targeted delivery of edaravone to ischemic areas where it provides significant local antioxidant and anti-inflammatory effects.

Clinical trial of edaravone in the treatment of traumatic cerebral infarction

Effect of edaravone against oxidative damage caused by acute craniocerebral trauma

Neuroprotective effect of edaravone on focal cerebral ischemia in rats

Clinical Observation on the Therapeutic Effect of Edaravone on Cerebral Infarction

Edaravone treatment in patients with cerebral infarction of atherosclerotic thrombus

Protective Effect of Edaravone on Free Radical Reaction after Cerebral Hemorrhage

Effect of Edaravone on Patients with Acute Moderate and Severe Brain Injury

Clinical Study in the Treatment of Craniocerebral Injury with Edaravone

Clinical observation in edaravone treatment for acute cerebral infarction

Protective Effects of Edaravone on Renal Ischemia-Reperfusion Injury in Rats

Clinical study of Edaravone Dexborneol combined with Tirofiban in treatment of Acute Cerebral Infarction

Clinical Observation on Efficacy of Edaravone in Treatment of Patients with Acute Cerebral Infarction

The effect of intra-arterial injection of edaravone on acute cerebral infarction

Influence of Edaravone on the Serum Levels of Vwf and Hs-Crp in Patients with Acute Cerebral Infarction

The experimental study of edaravone injection in rats traumatic brain injury

Clinical Study of Edaravone on the Patients with Progressive Stroke

Curative Effect of Edaravone Combined with Naloxone on Acute Brain Infarction

Effect of Edaravone on neuromotor function and ultrastructure of brain tissue after traumatic brain injury in rats

Influence of edaravone on the serum levels of MMP-9 and RIMP-1 in patients with acute cerebral infarction

Targeted Therapy of Ischemic Stroke Via Crossing the Blood-Brain Barrier Using Edaravone-Loaded Multiresponsive Microgels.

Study of Free Radical Scavenger for the Treatment of Acute Intracerebral Hemorrhage